PRKCA and glioblastoma: While PBM did not affect 200 nM hypericin-PDT, a higher concentration of 500 nM hypericin-PDT resulted in a greater reduction of PKCα in glioblastoma cells pretreated with PBM (PBM-hypericin-PDT).